Glaukos Corporation (GKOS) Stock Score, Valuation & Financial Research
Glaukos Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for GKOS
Glaukos Corporation currently has a Wall Street Score of 25/100. The stored market price is $167.25. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.7 points. These figures are a research snapshot, not a buy or sell recommendation.
What Glaukos Corporation does
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internat
GKOS financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $167.25
- Market capitalization:
- $9.87B
- Revenue:
- $612.8M
- Net income:
- $-188.0M
- Free cash flow:
- $-54.0M
- Cash:
- $114.5M
- Total debt:
- $102.8M
- EPS:
- -3.28
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 38/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-54.0M, showing cash burn in the current stored period.
- The balance sheet shows $114.5M of cash versus $102.8M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.7 points: GKOS increased 0.7 points because Revenue improved by 8.2 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GKOS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.